دورية أكاديمية
أعرض في EDS

The Experience of Implementing a National Antimicrobial Resistance Surveillance System in Brazil.

التفاصيل البيبلوغرافية
العنوان: The Experience of Implementing a National Antimicrobial Resistance Surveillance System in Brazil.
المؤلفون: Pillonetto M; State Laboratory for Public Health, Department of Health Assistance and Surveillance, Secretary of Health, Curitiba, Brazil.; Laboratory of Medical Microbiology, School of Medicine, Pontifical Catholic University, Curitiba, Brazil., Jordão RTS; General Coordination for Public Health Laboratories, Health Surveillance Secretary, Ministry of Health, Brasília, Brazil., Andraus GS; Laboratory of Medical Microbiology, School of Medicine, Pontifical Catholic University, Curitiba, Brazil., Bergamo R; State Laboratory for Public Health, Department of Health Assistance and Surveillance, Secretary of Health, Curitiba, Brazil., Rocha FB; General Coordination for Public Health Laboratories, Health Surveillance Secretary, Ministry of Health, Brasília, Brazil., Onishi MC; Infection Control Team and Clinical Microbiology Laboratory, Hospital Nossa Senhora das Graças, Curitiba, Brazil., de Almeida BMM; Infection Control Team and Clinical Microbiology Laboratory, Hospital de Clínicas, Federal University of Parana, Curitiba, Brazil., Nogueira KDS; Infection Control Team and Clinical Microbiology Laboratory, Hospital de Clínicas, Federal University of Parana, Curitiba, Brazil., Dal Lin A; Infection Control Team and Clinical Microbiology Laboratory, Hospital Marcelino Champagnat, Marista Group, Curitiba, Brazil., Dias VMCH; Infection Control Team and Clinical Microbiology Laboratory, Hospital Nossa Senhora das Graças, Curitiba, Brazil.; Infection Control Team and Clinical Microbiology Laboratory, Hospital Marcelino Champagnat, Marista Group, Curitiba, Brazil., de Abreu AL; General Coordination for Public Health Laboratories, Health Surveillance Secretary, Ministry of Health, Brasília, Brazil.
المصدر: Frontiers in public health [Front Public Health] 2021 Jan 14; Vol. 8, pp. 575536. Date of Electronic Publication: 2021 Jan 14 (Print Publication: 2020).
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Frontiers Editorial Office Country of Publication: Switzerland NLM ID: 101616579 Publication Model: eCollection Cited Medium: Internet ISSN: 2296-2565 (Electronic) Linking ISSN: 22962565 NLM ISO Abbreviation: Front Public Health Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Lausanne : Frontiers Editorial Office
مواضيع طبية MeSH: Anti-Bacterial Agents*/pharmacology , Anti-Infective Agents*, Brazil/epidemiology ; Drug Resistance, Bacterial ; Female ; Humans ; Male ; Pilot Projects
مستخلص: Antimicrobial resistance (AMR) is a major public health threat of global proportions, which has the potential to lead to approximately ten million deaths per year by 2050. Pressured by this wicked problem, in 2014, the World Health Organization launched a call for member states to share AMR data through the implementation of the Global Antimicrobial Resistance Surveillance System (GLASS), to appropriately scale and monitor the general situation world-widely. In 2017, Brazil joined GLASS and, in 2018, started its own national antimicrobial surveillance program (BR-GLASS) to understand the impact of resistance in the country. We compiled data obtained from the complete routine of three hospitals' microbiology labs during the year of 2018. This pilot data sums up to 200,874 antimicrobial susceptibility test results from 11,347 isolates. It represents 119 different microorganisms recovered from 44 distinct types of clinical samples. Specimens came from patients originating from 301 Brazilian cities, with 4,950 of these isolates from presumed Healthcare-Associated Infections (HAIs) and the other 6,397 community-acquired cases. The female population offered 58% of the collected samples, while the other 42% were of male origin. The urinary tract was the most common topography (6,372/11,347 isolates), followed by blood samples (2,072/11,347). Gram-negative predominated the bacterial isolates: Escherichia coli was the most prevalent in general, representing 4,030 isolates (89.0% of these from the urinary tract). Coagulase-negative Staphylococci were the most prevalent bacteria in blood samples. Besides these two species, the ESKAPE group have consolidated their prevalence. Regarding drug susceptibility results, 141,648 (70.5%) were susceptible, 9,950 (4.9%) intermediate, and 49,276 (24.5%) resistant. Acinetobacter baumannii was the most worrisome microorganism, with 65.3% of the overall antimicrobial susceptibility tests showing resistance, followed by ESBL-producing Klebsiella pneumoniae , with a global resistance rate of 59%. Although this is a pilot project (still limited to one state), this database shows the importance of a nation-wide surveillance program,[153mm][-12mm] Q14 especially considering it already had patients coming from 301 distinct counties and 18 different states. The BR-GLASS Program is an ongoing project that intends to encompass at least 95 hospitals distributed in all five geographical regions in Brazil within the next 5 years.
Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
(Copyright © 2021 Pillonetto, Jordão, Andraus, Bergamo, Rocha, Onishi, Almeida, Nogueira, Dal Lin, Dias and Abreu.)
References: Braz J Infect Dis. 1998 Jun;2(3):160-163. (PMID: 11103003)
Nat Rev Microbiol. 2012 Mar 16;10(4):266-78. (PMID: 22421879)
Emerg Infect Dis. 2016 Oct;22(10):1849-51. (PMID: 27648951)
Diagn Microbiol Infect Dis. 2013 Dec;77(4):337-40. (PMID: 24074766)
Rev Argent Microbiol. 2018 Jul - Sep;50(3):327-333. (PMID: 29548732)
Am J Infect Control. 2015 Feb;43(2):137-40. (PMID: 25541337)
Clin Microbiol Rev. 2005 Oct;18(4):657-86. (PMID: 16223952)
J Clin Microbiol. 2010 May;48(5):1562-9. (PMID: 20220167)
Clin Infect Dis. 2014 Jan;58 Suppl 1:S20-7. (PMID: 24343828)
Microbiol Spectr. 2019 Mar;7(2):. (PMID: 30900543)
BMC Microbiol. 2010 Aug 12;10:217. (PMID: 20704733)
J Infect Dev Ctries. 2014 Feb 13;8(2):160-7. (PMID: 24518625)
Antimicrob Agents Chemother. 2014 Dec;58(12):7592-4. (PMID: 25288087)
J Hosp Infect. 2018 Jul;99(3):318-324. (PMID: 29522784)
Antimicrob Agents Chemother. 2009 Jan;53(1):333-4. (PMID: 19015350)
Front Cell Infect Microbiol. 2017 Mar 13;7:55. (PMID: 28348979)
Diagn Microbiol Infect Dis. 2019 Feb;93(2):140-142. (PMID: 30355469)
Braz J Microbiol. 2008 Oct;39(4):623-30. (PMID: 24031278)
Euro Surveill. 2018 Oct;23(42):. (PMID: 30352643)
Clin Microbiol Rev. 2008 Jul;21(3):538-82. (PMID: 18625687)
Front Microbiol. 2016 Jun 13;7:895. (PMID: 27379038)
Clin Microbiol Rev. 2007 Jul;20(3):440-58, table of contents. (PMID: 17630334)
Braz J Microbiol. 2016 Dec;47 Suppl 1:31-37. (PMID: 27825605)
Am J Infect Control. 2018 Apr;46(4):387-392. (PMID: 29217187)
Antimicrob Agents Chemother. 2009 Jun;53(6):2702. (PMID: 19332672)
Clin Microbiol Rev. 2020 May 13;33(3):. (PMID: 32404435)
J Antimicrob Chemother. 2005 Oct;56(4):761-4. (PMID: 16115825)
Curr Microbiol. 2019 Jun;76(6):666-672. (PMID: 30941540)
J Hosp Infect. 2012 Apr;80(4):351-3. (PMID: 22382275)
Biotechnol Adv. 2019 Jan - Feb;37(1):177-192. (PMID: 30500353)
Braz J Infect Dis. 2001 Aug;5(4):200-14. (PMID: 11712965)
Braz J Infect Dis. 2017 Jan - Feb;21(1):57-62. (PMID: 27916604)
Front Cell Infect Microbiol. 2018 Jan 22;8:4. (PMID: 29404282)
BMC Infect Dis. 2015 Nov 25;15:545. (PMID: 26607324)
Rev Soc Bras Med Trop. 2019 Jun 27;52:e20180348. (PMID: 31271614)
J Infect Chemother. 2015 Apr;21(4):316-8. (PMID: 25585523)
Rev Inst Med Trop Sao Paulo. 2000 Jul-Aug;42(4):201-7. (PMID: 10968883)
J Clin Microbiol. 2003 Jul;41(7):3403-6. (PMID: 12843104)
Intern Med J. 2005 Dec;35 Suppl 2:S3-16. (PMID: 16271060)
J Clin Microbiol. 2011 May;49(5):1866-71. (PMID: 21411591)
Infect Genet Evol. 2017 Apr;49:130-133. (PMID: 27923770)
Int J Antimicrob Agents. 2005 May;25(5):358-73. (PMID: 15848289)
Front Cell Infect Microbiol. 2017 Feb 15;7:39. (PMID: 28261568)
J Infect Dis. 2008 Apr 15;197(8):1079-81. (PMID: 18419525)
Microbiol Mol Biol Rev. 2016 Jun 15;80(3):629-61. (PMID: 27307579)
فهرسة مساهمة: Keywords: BR-GLASS; Brazil; GLASS - Global Antimicrobial Resistance Surveillance System; antimicrobial resistance; antimicrobial susceptibility tests; multiresistant bacteria; public health; surveillance
المشرفين على المادة: 0 (Anti-Bacterial Agents)
0 (Anti-Infective Agents)
تواريخ الأحداث: Date Created: 20210201 Date Completed: 20210514 Latest Revision: 20210514
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC7841397
DOI: 10.3389/fpubh.2020.575536
PMID: 33520909
قاعدة البيانات: MEDLINE
الوصف
تدمد:2296-2565
DOI:10.3389/fpubh.2020.575536